Hopes rise of therapy for cystic fibrosis: Researchers in US demonstrate that gene treatment can correct disorder

THE FIRST evidence that the revolutionary technique of gene therapy works on humans with cystic fibrosis - the most common inherited disorder of northern Europeans - has emerged from research in the United States.

Scientists reported at a conference this week in Dallas, Texas, that they have successfully treated cystic fibrosis patients using gene therapy, where healthy versions of a defective gene are inserted into human tissue.

They emphasised that the research, which will be published in full next week, is still only preliminary and so far they have only demonstrated that it works on the noses of three patients.

In order for cystic fibrosis patients to benefit, gene therapy must work in their lungs, which become clogged with sticky mucus because of a defective gene that prevents the normal transport of chloride in and out of the cells lining the respiratory system.

Michael Welsh and colleagues from the Howard Hughes Medical Institute at the University of Iowa presented the results at the North American Cystic Fibrosis Conference. Further details will be published in the scientific journal Cell.

'I'm cautiously hopeful,' Dr Welsh said. ''But I think many more questions need to be answered. The really, really important issue is safety.'

The researchers sprayed the noses of their patients with the common cold virus, which they had genetically engineered to carry the normal version of the cystic fibrosis gene into defective cells. Dr Welsh found the inserted gene worked and the chloride defect was corrected.

However, large doses of the genetically altered virus will be needed in order to infect the cells lining the lungs, which may result in side-effects not seen in the three patients who received lower doses.

Nevertheless, Robert Beall of the US Cystic Fibrosis Foundation, said: ''I think it's a major milestone. We have to be very encouraged about this.'

Duncan Geddes, director of respiratory medicine at the National Heart and Lung Hospital in London, which began gene therapy trials on cystic fibrosis patients last August, said: 'This is an important first step on the long road towards gene therapy.'

His team is attempting to inject genes using fatty droplets, called liposomes, rather than viruses. A group of nine patients - all men - are taking part in the British trial. Three will receive a placebo, and six will receive liposomes carrying the gene.

A spokeswoman for the Cystic Fibrosis Research Trust in Britain said results of the trial were expected before the end of the year.

If gene therapy proves to work in the lungs of patients, it will have to be repeated on a regular basis because the respiratory system is constantly renewing the cells lining the lungs. Dr Geddes said the unanswered questions were how big the gene therapy doses will need to be, and how often they will have to be applied.

There are about 7,000 people, mostly children, suffering from cystic fibrosis in Britain. They are prone to recurrent lung infections that can lead to respiratory failure. Although antibiotics can prolong life expectancy, there is no cure for the disorder and many patients die in childhood.

The virus used in Dr Welsh's experiments was constructed by scientists at Genzyme, a biotechnology company based in Framingham, Massachusetts.

Two other US research teams - headed by Ronald Crystal, of Cornell University, and James Wilson, of the University of Pennsylvania - are conducting similar experiments. They are administering gene-carrying viruses directly to the lungs.

'They should be congratulated. It's great,' Dr Wilson said of the Iowa group's findings. He has so far treated two patients but not released any results.

However, he and Dr Crystal warned that much more work needs to be done.

Dr Crystal, who has treated three patients, said: 'It's a demonstration that you can correct the abnormality in the nose, but the disease is not in the nose.'

Start your day with The Independent, sign up for daily news emails
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs General

Guru Careers: Software Developer / C# Developer

£40-50K: Guru Careers: We are seeking an experienced Software / C# Developer w...

Guru Careers: Software Developer

£35 - 40k + Benefits: Guru Careers: We are seeking a Software Developer (JavaS...

SThree: Trainee Recruitment Consultant / Resourcer

£18000 - £23000 per annum + Commission: SThree: As a Trainee Recruitment Consu...

Ashdown Group: UI Developer - (UI, HTML, CSS, JavaScript, AngularJS)

£25000 - £40000 per annum: Ashdown Group: UI Developer - (UI, JavaScript, HTML...

Day In a Page

Sun, sex and an anthropological study: One British academic's summer of hell in Magaluf

Sun, sex and an anthropological study

One academic’s summer of hell in Magaluf
From Shakespeare to Rising Damp... to Vicious

Frances de la Tour's 50-year triumph

'Rising Damp' brought De la Tour such recognition that she could be forgiven if she'd never been able to move on. But at 70, she continues to flourish - and to beguile
'That Whitsun, I was late getting away...'

Ian McMillan on the Whitsun Weddings

This weekend is Whitsun, and while the festival may no longer resonate, Larkin's best-loved poem, lives on - along with the train journey at the heart of it
Kathryn Williams explores the works and influences of Sylvia Plath in a new light

Songs from the bell jar

Kathryn Williams explores the works and influences of Sylvia Plath
How one man's day in high heels showed him that Cannes must change its 'no flats' policy

One man's day in high heels

...showed him that Cannes must change its 'flats' policy
Is a quiet crusade to reform executive pay bearing fruit?

Is a quiet crusade to reform executive pay bearing fruit?

Dominic Rossi of Fidelity says his pressure on business to control rewards is working. But why aren’t other fund managers helping?
The King David Hotel gives precious work to Palestinians - unless peace talks are on

King David Hotel: Palestinians not included

The King David is special to Jerusalem. Nick Kochan checked in and discovered it has some special arrangements, too
More people moving from Australia to New Zealand than in the other direction for first time in 24 years

End of the Aussie brain drain

More people moving from Australia to New Zealand than in the other direction for first time in 24 years
Meditation is touted as a cure for mental instability but can it actually be bad for you?

Can meditation be bad for you?

Researching a mass murder, Dr Miguel Farias discovered that, far from bringing inner peace, meditation can leave devotees in pieces
Eurovision 2015: Australians will be cheering on their first-ever entrant this Saturday

Australia's first-ever Eurovision entrant

Australia, a nation of kitsch-worshippers, has always loved the Eurovision Song Contest. Maggie Alderson says it'll fit in fine
Letterman's final Late Show: Laughter, but no tears, as David takes his bow after 33 years

Laughter, but no tears, as Letterman takes his bow after 33 years

Veteran talkshow host steps down to plaudits from four presidents
Ivor Novello Awards 2015: Hozier wins with anti-Catholic song 'Take Me To Church' as John Whittingdale leads praise for Black Sabbath

Hozier's 'blasphemous' song takes Novello award

Singer joins Ed Sheeran and Clean Bandit in celebration of the best in British and Irish music
Tequila gold rush: The spirit has gone from a cheap shot to a multi-billion pound product

Join the tequila gold rush

The spirit has gone from a cheap shot to a multi-billion pound product
12 best statement wallpapers

12 best statement wallpapers

Make an impact and transform a room with a conversation-starting pattern
Paul Scholes column: Does David De Gea really want to leave Manchester United to fight it out for the No 1 spot at Real Madrid?

Paul Scholes column

Does David De Gea really want to leave Manchester United to fight it out for the No 1 spot at Real Madrid?